Selling, General, and Administrative Costs: Alkermes plc vs Opthea Limited

A Tale of Two Companies: Alkermes plc vs Opthea Limited

In the ever-evolving landscape of pharmaceutical and biotechnology industries, understanding operational costs is crucial. This chart provides a fascinating glimpse into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Opthea Limited from 2014 to 2023. Over this decade, Alkermes plc has consistently outpaced Opthea Limited in SG&A expenses, with a peak in 2023 where their costs were approximately 15 times higher than Opthea's. Notably, Alkermes saw a significant increase of around 245% in SG&A expenses from 2014 to 2023, reflecting their expansive growth strategy. Meanwhile, Opthea Limited, although smaller in scale, demonstrated a remarkable 1,480% increase in the same period, indicating aggressive scaling efforts. The data for 2024 is incomplete, leaving room for speculation on future trends. This comparison highlights the diverse strategies and growth trajectories within the sector.